[1]唐文军a,闫其星b,陈进芳b,等.卵巢癌患者MMP-2 基因rs243866，rs243842 和rs243865 位点多态性与含铂化疗方案疗效及不良反应的相关性研究[J].现代检验医学杂志,2023,38(01):6-10+37.[doi:10.3969/j.issn.1671-7414.2023.01.002]
　TANG Wen-juna,YAN Qi-xingb,CHEN Jin-fangb,et al.Association of rs243866，rs243842 and rs243865 Polymorphisms in MMP-2 Gene with Response and Adverse Reactions of Platinum-based Chemotherapy in Advanced Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2023,38(01):6-10+37.[doi:10.3969/j.issn.1671-7414.2023.01.002]
点击复制

卵巢癌患者MMP-2 基因rs243866，rs243842 和rs243865 位点多态性与含铂化疗方案疗效及不良反应的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年01期
页码:
6-10+37
栏目:
论著
出版日期:
2023-01-15

文章信息/Info

Title:
Association of rs243866，rs243842 and rs243865 Polymorphisms in MMP-2 Gene with Response and Adverse Reactions of Platinum-based Chemotherapy in Advanced Ovarian Cancer
文章编号:
1671-7414（2023）01-006-06
作者:
唐文军a; 闫其星b; 陈进芳b; 方 草b
(海南医学院第二附属医院 a. 肿瘤内科；b. 药学部，海口 570311)
Author(s):
TANG Wen-juna; YAN Qi-xingb; CHEN Jin-fangb; FANG Caob
（a.Department of Oncology; b. Department of Pharmacy, the Second Affiliated Hospital of Hainan Medical College, Haikou 570311, China）
关键词:
卵巢癌; 基质金属蛋白酶2- 基因多态性; 化疗不良反应
分类号:
R737.31；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.01.002
文献标志码:
A
摘要:
目的 探讨卵巢癌（ovarian cancer）患者基质金属蛋白酶 (matrix metalloproteinase，MMP)-2 基因rs243866，rs243842 和rs243865 的多态性与其含铂化疗方案的疗效和不良反应的关系。方法 选取2018 年12 月～ 2021 年12 月在海南医学院第二附属医院经病理确诊、一线接受含铂化疗方案治疗并具有完整资料的卵巢癌患者126 例。化疗前采集患者3ml 外周静脉血，采用多重PCR 扩增目标区域后再进行高通量测序，鉴定rs243866，rs243842 和rs243865 的基因型。分析其与含铂方案疗效及不良反应的相关性。结果 109 例患者可评估疗效，其中完全缓解（complete response，CR）/ 部分缓解(partial response，PR) 或疾病稳定（stable disease，SD）/ 疾病进展（progressive disease，PD）的患者分别为78 例和31 例。126 例患者中发生Ⅲ～Ⅳ级血液学毒性和消化道毒性的分别有33 例和16 例。MMP-2 基因rs243866 多态性与含铂化疗方案的疗效及不良反应均相关，携带G 等位基因的卵巢癌患者具有更好的疗效，其CR/PR 率为74.6%，显著高于携带A 等位基因（25.4%）的患者（OR=3.148，95%CI：1.362 ～ 7.441）。携带A 等位基因的患者Ⅲ～Ⅳ级血液学毒性的发生率为60%，显著高于携带G 等位基因（22.5%）的患者(OR=5.176，95%CI：2.193 ～ 12.217)。rs243842和rs243865 位点各基因型分布及等位基因分布频次与含铂方案的疗效及不良反应均无相关性。结论 携带 rs243866 G等位基因的晚期卵巢癌患者在接受含铂方案治疗时具有较好的疗效和较低Ⅲ / Ⅳ血液学毒性。
Abstract:
Objective To evaluate the association of matrix metalloproteinase (MMP) -2 gene polymorphisms with response and adverse reactions of platinum-based chemotherapy in advanced ovarian cancer. Methods A total of 126 cases with pathologically confirmed at the Second Affiliated Hospital of Hainan Medical University during December 2018 to December 2021 were collected which received platinum- based chemotherapy and all of them with complete data. 3ml of peripheral venous blood sample was obtained from each patient before chemotherapy, then single nucleotide polymorphism of rs243866, rs243842 and rs243865 was conducted using high throughout sequencing technology. The relationship among the genotypes with chemotherapeutic response and adverse reactions was analyzed. Results 109 patients could be evaluated for curative effect, among which 78 patients were complete response（CR）/ partial response(PR) and 31 patients were stable disease（SD）/ progressive disease（PD）.33 patients had grade Ⅲ～Ⅳ hematological toxicity and 16 patients had grade Ⅲ～Ⅳ gastrointestinal toxicity in all 126 patients. The polymorphism of rs243866 were related with the chemotherapeutic response and adverse reactions, and the chemotherapy CR/PR rate of patients with G allele was 74.6%. Compared with A allele（25.4%）, individuals with G allele had a higher chemotherapy response (OR=3.148，95%CI: 1.362 ～ 7.441). The incidence of grade Ⅲ ~ Ⅳ hematologic toxicity in patients with A allele was 60%, and carrying A allele（22.5%） was related with higher risk of hematologic toxicity (OR=5.176，95%CI: 2.193 ～ 12.217). The polymorphisms of rs243842 and rs243865 were not statistically related with the chemotherapeutic response and adverse reactions. Conclusion Patients with advanced ovarian cancer who carried the rs243866 G allele had better efficacy and Ⅲ / Ⅳ lower hematological toxicity when treated with platinum-based chemotherapy.

参考文献/References:

[1] PENNY S M. Ovarian cancer: an overview[J].Radiologic Technology, 2020, 91(6): 561-575.
[2] MORAND S, DEVANABOYINA M, STAATS H, et al. Ovarian cancer immunotherapy and personalized medicine[J].International Journal of Molecular Sciences, 2021, 22(12): 6532.
[3] DAMIA G, BROGGINI M. Platinum resistance in Ovarian cancer: role of DNA repair[J]. Cancers, 2019,11(1): 119.
[4] L? Yaqi, ZHAO Xiangmei, ZHU Lidan, et al. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis[J]. Theranostics, 2018, 8(10): 2830-2845.
[5] DOFARA S G, CHANG S L, DIORIO C. Gene polymorphisms and circulating levels of MMP-2 and MMP-9: A review of their role in breast cancer risk[J]. Anticancer Research, 2020, 40(7): 3619-3631.
[6] BIA?KOWSKA K, MARCINIAK W, MUSZY?SKA M, et al. Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast,lung and colon cancer risk in Polish population[J].Hereditary Cancer in Clinical Practice, 2020, 18(1): 16.
[7] PERES L C, CUSHING-HAUGEN K L, K?BEL M,et al. Invasive epithelial ovarian cancer survival by histotype and disease stage[J]. Journal of the National Cancer Institute, 2019, 111(1): 60-68.
[8] 朱家凤, 苏琦. 基于GEO 数据筛选卵巢癌细胞对紫杉醇耐药基因及相关分子机制与治疗药物实验探讨[J]. 现代检验医学杂志, 2022, 37(1): 92-96, 158.
ZHU Jiafeng, SU Qi. Screening of paclitaxel resistant genes and related molecular mechanisms of ovarian cancer cells based on GEO data and experimental study of therapeutic drugs [J]. Journal of Modern Laboratory Medicine, 2022, 37(1）:92-96, 158.
[9] YAN Yang, FANG Lanlan, LI Yuxi, et al. Association of MMP2 and MMP9 gene polymorphisms with the recurrent spontaneous abortion: A meta-analysis [J].Gene, 2021, 767: 145173.
[10] LIU Chang, LI Ying, HU Shasha, et al. Clinical significance of matrix metalloproteinase-2 in endometrial cancer: A systematic review and metaanalysis[J]. Medicine, 2018, 97(29): e10994.
[11] CAREY P, LOW E, HARPER E, et al. Metalloproteinases in ovarian cancer[J]. International Journal of Molecular Sciences, 2021, 22(7): 3403.
[12] JELENIEWICZ W, CYBULSKI M, NOWAKOWSKI A, et al. MMP-2 mRNA expression in ovarian cancer tissues predicts patients’ response to Platinum-Taxane chemotherapy[J]. Anticancer Research, 2019, 39(4):1821-1827.
[13] VOS M C, VAN TILBORG A, BRANDS W J, et al.Polymorphisms in MMP-14 and MMP-2 genes and ovarian cancer survival[J]. Cancer Biomarkers : Section a of Disease Markers, 2019, 25(3): 233 ～ 241.
[14] JIA Honglei, ZHANG Qingzu, LIU Fanxiao, et al.Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis[J]. Archives of Gynecology and Obstetrics,2017, 295(3): 689-696.
[15] MORALES-V?SQUEZ F, CASTILLO-S?NCHEZ R,G?MORA M J, et al. Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors[J].Journal of Ovarian Research, 2020, 13(1): 86.
[16] FU Ziyi, XU Sujuan, XU Ye, et al. The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer[J]. International Journal of Gynecological Cancer, 2015, 25(3): 356-362.
[17] RITTER A M V, RITTER A, DE FARIA A P, BARBARO N R, et al. The rs243866/243865 polymorphisms in MMP-2 gene and the relationship with BP control in obese resistant hypertensive subjects[J]. Gene, 2018,646(646): 129-135.
[18] HARENDZA S, LOVETT D H, PANZER U, et al.Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness[J]. The Journal of Biological Chemistry, 2003, 278(23): 20490-20499.
[19] HUA Yihong, SONG Li, WU Naqiong, et al. Polymorphisms of MMP-2 gene are associated with systolic heart failure prognosis[J]. Clinica Chimica Acta, 2009,404(2): 119-123.
[20] LIU Kun, GU Shuo, LIU Xuzhong, et al. The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis[J]. Oncotarget, 2017, 8(42):72933-72938.
[21] KAWAL P, CHANDRA A, PHOLA T N, et al.Correlations of polymorphisms in matrix metallo proteinase-1, -2, and -7 promoters to susceptibility to malignant gliomas[J]. Asian J Neurosarg, 2016, 11(2):160-166.
[22] ZHOU Yifeng, YU Chunyuan, MIAO Xiaoping, et al.Substantial reduction in risk of breast cancer associated with genetic polymerphisms in the promoters of the matrix metallop-roteinase-2 and tissue inhibitor of metallo proteinase-2 gens[J].Carcinogenesis, 2004,25(3):399-404.
[23] LEI Haixin, HEMMINKI K, ALTIERI A, et al.Promoter polymorphisms in matrix metallo proteinases and their inhibitors: few associations with breast cancer susceptibility and progression[J]. Breast Cancer Res Treat, 2007,103(1): 61-69.
[24] ROEHE A D, FRAZION A P, AGNES G, et al.Detection of plymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in south brazil: preliminary results[J]. Breast Cancer Res Treat, 2007, 102(1): 123-124.
[25] LEE J, CHOI J, CHUNG S, et a l. Genet ic predisposition of polymorphisms in HMG B1-related genes to breast cancer prognosis in Korean women[J]. J Breast Cancer, 2017, 20(1): 27-34.
[26] MANSO H, KRUG T, SOBRAL J, et al. Variants of the matrix metalloproteinase-2 but not the matrix metalloproteinase-9 genes significantly influence functional outcome after stroke[J]. BMC Medical Genetics, 2010, 11(1): 40.
[27] ZHAO Xueying, WANG Xun, WU Wenting, et al.Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy[J]. Cancer, 2012, 118(14): 3587-3598.

相似文献/References:

[1]顾益凤,朱自力,张金业,等.利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点[J].现代检验医学杂志,2015,30(04):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
　GU Yi-feng,ZHU Zi-li,ZHANG Jin-ye,et al.Selecting the Best Cut-off Point of Serum HE-4 in Ovarian Cancer by ROC Curve[J].Journal of Modern Laboratory Medicine,2015,30(01):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
[2]郑福利,张颖,王建.血清S100A6检测对卵巢上皮性癌的诊断价值[J].现代检验医学杂志,2015,30(05):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
　ZHENG Fu-li,ZHANG Ying,WANG Jian.Study on Diagnostic Value of Detecting Serum S100A6 in the Epithelial Ovarian Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(01):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
[3]詹颉,常宁宁,李小侠,等.CEA，AFP，CA125，CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J].现代检验医学杂志,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
　ZHAN Jie,CHANG Ning-ning,LI Xiao-xia,et al.Clinical Value of Combined Detection of CEA，AFP，CA125，CA199 and CA72-4 in the Identification of Ovarian Benign and Malignant Disease[J].Journal of Modern Laboratory Medicine,2015,30(01):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
[4]邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
　XING Rui-qing,WU Yong-chang,CHEN Hui-yu,et al.Diagnostic Value of Serum CA125,HE4 and ROMA Index in Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
[5]张 悦a,段海霞,暴 蕾a,等.microRNA-125b在葛根素诱导人卵巢癌细胞SKOV3凋亡中的作用研究[J].现代检验医学杂志,2017,32(05):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
　ZHANG Yuea,DUAN Hai-xia,BAO Leia,et al.Role of MicroRNA-125b in Human Ovarian Cancer Cell SKOV3 Induced Apoptosis by Puerarin[J].Journal of Modern Laboratory Medicine,2017,32(01):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
[6]徐金良a,杜丹丹,翟志敏,等.卵巢良恶性肿瘤患者血液NLR,LMR,RDW,PLR四项参数的变化及其临床意义[J].现代检验医学杂志,2018,33(02):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　XU Jin-lianga,DU Dan-dan,ZHAI Zhi-min,et al.Changes and Clinical Significance of Four Parameters of NLR,LMR, RDW and PLR in Patients with Benign and Malignant Ovarian Tumors[J].Journal of Modern Laboratory Medicine,2018,33(01):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]马同敏,赵志强.血清CA125,STIP1和IGF-Ⅰ联合检测对卵巢癌的早期诊断价值研究[J].现代检验医学杂志,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
　MA Tong-min,ZHAO Zhi-qiang.Clinical Value of Combined Detection of Serum CA125,STIP1 and IGF-I Levels in Early Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
[8]张善弟,荆成宝,禹 梅.血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值[J].现代检验医学杂志,2018,33(06):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
　ZHANG Shan-di,JING Cheng-bao,YU Mei.Clinical Value of Combined Detection of Serum CEA,CA125 and HE4 in the Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
[9]刘 青,邓慧敏,周林涛,等.卵巢癌患者组织中miR-135b的表达及临床意义[J].现代检验医学杂志,2019,34(02):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
　LIU Qing,DENG Hui-min,ZHOU Lin-tao,et al.Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2019,34(01):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
[10]侯 娟,蒋树立,滕长财.基于TCGA 数据库卵巢癌患者的miR-301b 表达量与生存状况生物信息学分析[J].现代检验医学杂志,2020,35(04):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
　HOU Juan,JIANG Shu-li,TENG Chang-cai.Bioinformatics Analysis of Mir-301b Expression and Survival Status of Patients with Ovarian Cancer Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2020,35(01):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]

备注/Memo

备注/Memo:
基金项目：海南省自然科学基金青年基金资助项目(NO.819QN362)。
作者简介： 唐文军（1983-），男，博士，副主任医师，主要从事肺癌及卵巢癌的早期诊断及个体化治疗。
闫其星（1986-），女，学士，副主任药师，主要从事抗肿瘤临床药学工作，E-mail:27569542@qq.com，并列第一作者。
通讯作者：方草，主任药师，主要从事临床药学与药事管理，E-mail: tjdaiyan@126.com。
更新日期/Last Update: 2023-01-15